Overview

IMPRESS study aims to describe the immuno-inflammatory and thrombo-inflammatory profiles during the first 24/36 hours of treatment of patients suffering from AIC treated with TM, and to study the possible impact of these profiles on the functional prognosis at 3 months of AIC treatment.

Eligibility

Inclusion Criteria:

• Presenting an acute ischemic stroke for which treatment by mechanical thrombectomy is indicated according to European and North American recommendations (associated or not with intravenous thrombolysis)

Exclusion Criteria:

• Intracranial haemorrhage associated with acute ischemic stroke on initial imaging
• Contraindication or non-indication to a mechanic thrombectomy
• Immunosuppressive treatment or corticosteroid therapy on admission of the patient
• Pre-existing neurological disability limiting the neurological assessment to 3 months (mRS>2 on admission)
• Dementia known and diagnosed pre-existing at acute ischemic stroke
• Pregnant or breastfeeding woman